First Horizon Advisors Inc. Grows Position in 10x Genomics, Inc. (NASDAQ:TXG)

First Horizon Advisors Inc. boosted its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 53.3% in the third quarter, Holdings Channel.com reports. The institutional investor owned 2,910 shares of the company’s stock after acquiring an additional 1,012 shares during the period. First Horizon Advisors Inc.’s holdings in 10x Genomics were worth $66,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in 10x Genomics by 451.8% during the third quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after buying an additional 1,265 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in shares of 10x Genomics in the 3rd quarter worth $35,000. Allspring Global Investments Holdings LLC increased its stake in 10x Genomics by 134.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,637 shares of the company’s stock worth $32,000 after acquiring an additional 939 shares during the last quarter. Blue Trust Inc. increased its position in shares of 10x Genomics by 136.5% during the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after purchasing an additional 1,025 shares during the last quarter. Finally, Sound Income Strategies LLC purchased a new position in 10x Genomics in the 3rd quarter worth about $46,000. Institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Performance

Shares of NASDAQ TXG opened at $14.31 on Monday. 10x Genomics, Inc. has a fifty-two week low of $12.95 and a fifty-two week high of $57.90. The company has a market cap of $1.73 billion, a PE ratio of -9.35 and a beta of 1.87. The business has a 50-day simple moving average of $17.57 and a two-hundred day simple moving average of $19.89.

10x Genomics (NASDAQ:TXG) last released its earnings results on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The company had revenue of $151.65 million during the quarter, compared to analysts’ expectations of $158.84 million. During the same period last year, the business earned ($0.51) EPS. 10x Genomics’s revenue for the quarter was down 1.3% on a year-over-year basis. On average, sell-side analysts predict that 10x Genomics, Inc. will post -1.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TXG has been the topic of a number of research analyst reports. JPMorgan Chase & Co. dropped their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. The Goldman Sachs Group dropped their price objective on 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a research note on Wednesday, October 30th. UBS Group decreased their target price on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, October 30th. Barclays dropped their price target on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, Leerink Partners began coverage on 10x Genomics in a report on Tuesday, September 3rd. They issued an “outperform” rating and a $35.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $29.19.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.